Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Common Equity (2019 - 2025)

Historic Common Equity for Benitec Biopharma (BNTC) over the last 7 years, with Q1 2025 value amounting to $317.7 million.

  • Benitec Biopharma's Common Equity rose 266221.74% to $317.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $317.7 million, marking a year-over-year increase of 266221.74%. This contributed to the annual value of $47.2 million for FY2024, which is 2329009.9% up from last year.
  • Per Benitec Biopharma's latest filing, its Common Equity stood at $317.7 million for Q1 2025, which was up 266221.74% from $281.5 million recorded in Q4 2024.
  • Over the past 5 years, Benitec Biopharma's Common Equity peaked at $317.7 million during Q1 2025, and registered a low of $202000.0 during Q2 2023.
  • Moreover, its 5-year median value for Common Equity was $14.6 million (2022), whereas its average is $50.4 million.
  • Per our database at Business Quant, Benitec Biopharma's Common Equity plummeted by 9299.1% in 2023 and then soared by 2329009.9% in 2024.
  • Quarter analysis of 5 years shows Benitec Biopharma's Common Equity stood at $10.8 million in 2021, then decreased by 17.0% to $9.0 million in 2022, then skyrocketed by 72.0% to $15.5 million in 2023, then surged by 1719.64% to $281.5 million in 2024, then rose by 12.84% to $317.7 million in 2025.
  • Its last three reported values are $317.7 million in Q1 2025, $281.5 million for Q4 2024, and $64.2 million during Q3 2024.